Innovation
Shining a light on the treatment of CNS disorders and cancer care.
SK Life Science is here listening to the needs of healthcare providers, patients, caregivers, advocates, and scientists. We are developing new molecules, enhancing advocacy efforts, and providing solutions that change what’s possible in the treatment of CNS disorders and cancer care.
Our Medicines
SK Life Science is committed to accelerating the development of next generation treatments for CNS disorders and cancer care. SK Biopharmaceuticals and SK Life Science independently developed XCOPRI® (cenobamate tablets) CV from inception through FDA approval.
For More Information
- XCOPRI Website
- XCOPRI Medication Guide
- XCOPRI Prescribing Information
- SK Life Science Navigator Program for Patient Access
The two companies also discovered and licensed-out the FDA and EMA-approved treatment for sleep disorders after completing phase 1 clinical trials.
U.S. Patent Rights For Products
This website is provided to satisfy the virtual patent marking provisions of the United States, including relevant provisions of the America Invents Act and 35 U.S. Code 287 (a).
The following products are protected by the associated U.S. patents set forth in the table below. The list is subject to change due to issuance of additional patents, product changes and other circumstances. The absence of a U.S. Patent number from the list does not constitute a waiver of the patent, trademark, or other intellectual property rights pertaining to the product.
- XCOPRI®
(cenobamate tablets) CV
U.S. Patent No. 7,598,279
U.S. Patent No. 11,654,133
For Healthcare Providers
Changing What’s Possible
For the latest scientific and clinical information about our medicines, please visit our medical information website. This resource provides up-to-date access to company-sponsored publications and recent medical conference presentations, helping you support your patients in leading healthier and happier lives.
For medical information inquiries on our medicines or to report adverse effects, please email us at Medicalinfo@SKLSI.com or call 1-866-OKSKLSI (657-5574).
Global Patient Safety
Ensuring the safety of patients is our top priority.
We do this through pharmacovigilance monitoring. For more information, please see here.
Our Clinical Trials
We are committed to conducting diverse, global clinical trials. With a commitment to safety, we place our patients at the center of everything we do.
To address the needs of the patient communities we serve, we are conducting the following clinical trials:
- Global Primary Generalized Tonic-Clonic (PGTC) Seizures Clinical Trial
Our global Phase 3 Open Label Safety Study for patients 12 years of age and older had sites in the U.S. as well as Bulgaria, Czechia, Georgia, Hungary, Poland, Slovakia, and Ukraine. - Global Pediatric Clinical Trial
We are currently enrolling in a Phase 3 Open Label Safety Study for patients between the ages of 2 and 3. The trial is currently recruiting in the U.S. as well as in Australia, Germany, Hungary, Poland, South Korea, and Spain. - Global LGS DISCOVER Study
The LGS DISCOVER study is evaluating whether an investigational drug can decrease the number of seizures in patients 4-55 years of age living with Lennox-Gastaut syndrome. The trial is currently recruiting in Australia, Colombia, Germany, Greece, Hungary, Italy, Korea, Mexico, Poland, Portugal, Serbia, Spain, Taiwan, and the U.S. For more information, please visit www.LGSDiscoverStudy.com. - Monotherapy Study
This is an open-label study to evaluate the effectiveness, safety and tolerability of an investigational drug used as a monotherapy in newly diagnosed or recurrent partial-onset seizures adult patients between the ages of 18 and 74. - Global Phase 1 Radiopharmaceutical Therapy Clinical Trial
This first-in-human, open-label, multicenter Phase 1 study is evaluating the safety, dose range, and biologically active dose of an investigational alpha-emitter radiopharmaceutical therapy (SKL35501) in patients with advanced solid tumors expressing NTSR1. The study is being conducted in the United States and South Korea and includes dose escalation followed by dose optimization and expansion.
Our Global Pipeline
SK Life Science and its parent company SK Biopharmaceuticals have 12 compounds under development globally.
| Compound | Indication |
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
NDA
Marketed
|
|---|---|---|
| Cenobamate |
Epilepsy – Focal Seizures
|
|
|
Epilepsy – Focal Seizures, Asia 1
|
||
|
Epilepsy – Generalized Seizures2
|
||
|
Epilepsy – Focal Seizures, Pediatric
|
||
| Solriamfetol (L/O to Axsome, Ignis) |
EDS3 in Narcolepsy, EDS in OSA4
|
|
| Carisbamate |
Lennox-Gastaut Syndrome
|
|
| SKL32276 |
Parkinson’s Diseases
(GCase Activator)
|
|
| SKL24741 |
Epilepsy
|
|
| SKL13865 |
ADHD
|
|
| SKL20540 |
Schizophrenia
|
|
| SKL35501 (FL-091) |
Oncology
(targeting NTSR1)
|
|
| SKL37321 (WT-7695) |
Oncology
(targeting CA9)
|
|
| ROR1 Project |
Oncology
(targeting ROR1)
|
|
| p300 Degrader |
Oncology
(targeting p300)
|
|
| Neuroimmune Project |
CNS
(targeting VAV1)
|
1) NDA approved in Korea, China(Nov. 2025, Dec. 2025 for each), Submitted NDA in Japan(Sep. 2025)
2) Primary Generalized Tonic-Clonic(PGTC) seizures, Phase 3 topline data obtained in Sep. 2025
3) Excessive Daytime Sleepiness
4) Obstructive Sleep Apnea
Invigorating Next Generation Discovery
We are a group of scientists, inventors, and explorers tirelessly working to develop solutions that will improve CNS and cancer care
Leveraging Technologies to Include:
- Target-based drug discovery techniques
- High throughput organic screening (HTOs)/high content screening (HCS)
- Computer-aided drug design (CADD)
- Combinatorial chemistry
Key R&D Sectors:
We deploy our technologies in the areas of biology/discovery, medicinal chemistry, and pharmacology. The goal of research in these areas is to bring meaningful products to market.
Select A Sector For Details
We are responsible for lead compound discovery and optimization. This sector:
- IDENTIFIES and validates signal and molecular targets
- DEVELOPS screening technologies
- PERFORMS high-throughput screening (HTS) leveraging technologies
- PARTICIPATES in joint studies on targets known to have high target-disease correlation
- INVESTIGATES the efficacy and safety of lead compounds
The medicinal chemistry sector of SK Life Science is responsible for:
- IDENTIFYING a wide array of drug candidates for the treatment of CNS disorders and cancer
- OPTIMIZING lead compounds in terms of their structure-activity relationships
- DEVELOPING processes for clinical candidates to lead compound discovery and optimization
To maximize efficiency, we have implemented a CADD system, a high-efficiency synthesis infrastructure, an established structure-diverse library, and a target focus library.
The pharmacology sector is responsible for research programs in which drug candidates are studied to enable prediction of drug activity in the human body.
Grant Requests
Medical Education Grant Request
Transparency
Vermont State Regulations
Long form disclosure for XCOPRI® (cenobamate tablets) CV
Short form disclosure for XCOPRI® (cenobamate tablets) CV